Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Oct 31, 2019 and accepted by EDGAR at Oct 31, 2019, 20:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $949.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $2.75bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-07-01 to 2019-09-30 | $131.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2019-01-01 to 2019-09-30 | $362.7m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $555.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $1.27bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-07-01 to 2019-09-30 | $159.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2019-01-01 to 2019-09-30 | $463.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | $99.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | $646.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-07-01 to 2019-09-30 | $13.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2019-01-01 to 2019-09-30 | $124.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-07-01 to 2019-09-30 | $57.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | $593.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | $0.22 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | $2.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-07-01 to 2019-09-30 | $0.22 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2019-01-01 to 2019-09-30 | $2.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-07-01 to 2019-09-30 | 260,473,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2019-01-01 to 2019-09-30 | 260,182,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | $1.12bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $58.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2019-01-01 to 2019-09-30 | $156.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-09-30 | $3.40bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $4.78bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $7.51bn | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $1.39bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $2.26bn | us-gaap:Liabilities |
Source: SEC EDGAR, the filing index for accession 0000875320-19-000057. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.